# Affini-T Therapeutics

Source: https://onco.cc/companies/affini-t-therapeutics/  
OnCo record `affini-t-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Affini-T engineers a patient's T cells with receptors that recognise mutated cancer driver proteins such as KRAS, and uses gene editing to make the cells more effective. It is an early clinical-stage company based near Boston.

## Summary

Affini-T Therapeutics is a Watertown, Massachusetts cell therapy company developing T-cell receptor (TCR) based T-cell therapies. Partner Metagenomi reported in August 2024 that it had established cGMP gene-editing reagents and filed Drug Master Files with the FDA to support an IND for Affini-T's TCR-based therapy, receiving 933,650 Affini-T shares on achievement of that regulatory milestone, which indicates the lead programme was at the IND stage in 2024. An SEC Form D filed in October 2024 shows the company was incorporated in 2020 and sold about $17.6 million of equity in an offering that began in July 2024. The company website is rendered client-side and returned no readable text to automated fetches, so programme names, targets and earlier financing rounds could not be confirmed from primary sources.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Watertown, MA
- Type: cell-therapy
- Website: https://www.affinittx.com/

## Notes

- Series letter for the 2024 Form D not stated.

## Sources

- Official website: https://www.affinittx.com/
- Form D, October 2024: https://www.sec.gov/Archives/edgar/data/2036455/000203645524000001/primary_doc.xml
- Metagenomi Q2 2024 results describing the Affini-T milestone (8-K): https://www.sec.gov/Archives/edgar/data/1785279/000095017024096673/mgx-ex99_1.htm

## Connected records

- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/)
- technologies: [TCR-T cell therapy](https://onco.cc/technologies/tcr-t/)
- trials: [Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor](https://onco.cc/trials/nct06105021/)
- companies: [Leaps by Bayer](https://onco.cc/companies/leaps-by-bayer/)

---
JSON: https://onco.cc/api/v1/entities/affini-t-therapeutics.json